Publication details

Léčba nemoci chladových aglutininů je založena na rituximabu v monoterapii, lépe však v kombinacích

Title in English Treatment of cold agglutinin disease is based on rituximab in monotherapy, combination treatment is however more successful
Authors

ADAM Zdeněk POUR Luděk KREJČÍ Marta

Year of publication 2017
Type Article in Periodical
Magazine / Source Postgraduální medicína
MU Faculty or unit

Faculty of Medicine

Citation
Field Oncology and hematology
Keywords cold agglutinin disease; treatment; rituximab
Description Correct diagnosis of cold agglutinin disease represents the key to the successful treatment. Warm antibodies are absent and hemolysis is caused by antibodies of the IgM class that are typically present in the form of paraprotein – the disorder shows features of low-grade lymphoproliferation. Steroids are not active the basic component of the treatment is rituximab that is combined in order to improve the efficacy of the therapy with other cytostatic drugs, more recently with bendamustine or bortezomib. Eculizumab can be successfully used in the cases of significant resistance to the combined immuno-chemotherapy.

You are running an old browser version. We recommend updating your browser to its latest version.

More info